159 related articles for article (PubMed ID: 34116129)
21. Autophagy is involved in the initiation and progression of Graves' orbitopathy.
Yoon JS; Lee HJ; Chae MK; Lee EJ
Thyroid; 2015 Apr; 25(4):445-54. PubMed ID: 25687157
[TBL] [Abstract][Full Text] [Related]
22. Disulfiram Exerts Antiadipogenic, Anti-Inflammatory, and Antifibrotic Therapeutic Effects in an
Wang X; Yang S; Ye H; Chen J; Shi L; Feng L; Wang X; Zhang T; Chen R; Xiao W; Yang H
Thyroid; 2022 Mar; 32(3):294-305. PubMed ID: 34605662
[No Abstract] [Full Text] [Related]
23. M1-Like Macrophages Modulate Fibrosis and Inflammation of Orbital Fibroblasts in Graves' Orbitopathy: Potential Relevance to Soluble Interleukin-6 Receptor.
Lu Y; Wang Y; Wang Y; Wu Y; Huang Y; Liu X; Zhang S; Zhong S; Li Y; Li B; Sun J; Fang S; Zhou H
Thyroid; 2023 Mar; 33(3):338-350. PubMed ID: 36617890
[No Abstract] [Full Text] [Related]
24. Integrative Analysis of Proteomics and DNA Methylation in Orbital Fibroblasts From Graves' Ophthalmopathy.
Virakul S; Somparn P; Pisitkun T; van der Spek PJ; Dalm VASH; Paridaens D; van Hagen PM; Hirankarn N; Palaga T; Dik WA
Front Endocrinol (Lausanne); 2020; 11():619989. PubMed ID: 33658982
[TBL] [Abstract][Full Text] [Related]
25. The Role of Sphingosine-1-Phosphate in Adipogenesis of Graves' Orbitopathy.
Kim SE; Lee JH; Chae MK; Lee EJ; Yoon JS
Invest Ophthalmol Vis Sci; 2016 Feb; 57(2):301-11. PubMed ID: 26830367
[TBL] [Abstract][Full Text] [Related]
26. TMEM2 inhibits the development of Graves' orbitopathy through the JAK-STAT signaling pathway.
Li H; Min J; Yang Y; Suo W; Wang W; Tian J; Qin Y
J Biol Chem; 2024 Feb; 300(2):105607. PubMed ID: 38159864
[TBL] [Abstract][Full Text] [Related]
27. Polydatin attenuates orbital oxidative stress in Graves' orbitopathy through the NRF2 pathway.
Li H; Min J; Chen Y; Li H; Zhang Y
Chem Biol Interact; 2020 Jan; 315():108894. PubMed ID: 31705858
[TBL] [Abstract][Full Text] [Related]
28. Role of Inositol-Requiring Enzyme 1 and Autophagy in the Pro-Fibrotic Mechanism Underlying Graves' Orbitopathy.
Lee CE; Kim JY; Yoon JS; Ko J
Yonsei Med J; 2024 Jul; 65(7):397-405. PubMed ID: 38910302
[TBL] [Abstract][Full Text] [Related]
29. Novel Roles of Chloroquine and Hydroxychloroquine in Graves' Orbitopathy Therapy by Targeting Orbital Fibroblasts.
Guo Y; Li H; Chen X; Yang H; Guan H; He X; Chen Y; Pokharel S; Xiao H; Li Y
J Clin Endocrinol Metab; 2020 Jun; 105(6):1906-17. PubMed ID: 32249902
[TBL] [Abstract][Full Text] [Related]
30. Neferine suppresses autophagy-induced inflammation, oxidative stress and adipocyte differentiation in Graves' orbitopathy.
Li H; Gao L; Min J; Yang Y; Zhang R
J Cell Mol Med; 2021 Feb; 25(4):1949-1957. PubMed ID: 33443817
[TBL] [Abstract][Full Text] [Related]
31. Therapeutic Effect of Resveratrol on Oxidative Stress in Graves' Orbitopathy Orbital Fibroblasts.
Kim CY; Lee HJ; Chae MK; Byun JW; Lee EJ; Yoon JS
Invest Ophthalmol Vis Sci; 2015 Oct; 56(11):6352-61. PubMed ID: 26436888
[TBL] [Abstract][Full Text] [Related]
32. High-Mobility Group Box 1 Is Associated with the Inflammatory Pathogenesis of Graves' Orbitopathy.
Han SY; Choi SH; Shin JS; Lee EJ; Han SH; Yoon JS
Thyroid; 2019 Jun; 29(6):868-878. PubMed ID: 30973094
[No Abstract] [Full Text] [Related]
33. Role of miR-146a in the Regulation of Inflammation in an In Vitro Model of Graves' Orbitopathy.
Jang SY; Chae MK; Lee JH; Lee EJ; Yoon JS
Invest Ophthalmol Vis Sci; 2016 Aug; 57(10):4027-34. PubMed ID: 27494344
[TBL] [Abstract][Full Text] [Related]
34. Therapeutic effect of ibrutinib, a selective Bruton's tyrosine kinase inhibitor, in orbital fibroblasts from patients with Graves' orbitopathy.
Park HY; Chae MK; Ko J; Kikkawa DO; Jang SY; Yoon JS
PLoS One; 2022; 17(12):e0279060. PubMed ID: 36521376
[TBL] [Abstract][Full Text] [Related]
35. Fibroblast Growth Factor Receptor Inhibitors Reduce Adipogenesis of Orbital Fibroblasts and Enhance Myofibroblastic Differentiation in Graves' Orbitopathy.
Shih SR; Liao SL; Shih CW; Wei YH; Lu TX; Chou CH; Yen EY; Chang YC; Lin CC; Chi YC; Yang WS; Tsai FC
Ocul Immunol Inflamm; 2021 Jan; 29(1):193-202. PubMed ID: 31657648
[No Abstract] [Full Text] [Related]
36. Mesenchymal Stem Cell-Like Properties of Orbital Fibroblasts in Graves' Orbitopathy.
Kozdon K; Fitchett C; Rose GE; Ezra DG; Bailly M
Invest Ophthalmol Vis Sci; 2015 Sep; 56(10):5743-50. PubMed ID: 26325413
[TBL] [Abstract][Full Text] [Related]
37. Alteration of Connective Tissue Growth Factor (CTGF) Expression in Orbital Fibroblasts from Patients with Graves' Ophthalmopathy.
Tsai CC; Wu SB; Chang PC; Wei YH
PLoS One; 2015; 10(11):e0143514. PubMed ID: 26599235
[TBL] [Abstract][Full Text] [Related]
38. 4-Methylumbelliferone suppresses hyaluronan and adipogenesis in primary cultured orbital fibroblasts from Graves' orbitopathy.
Yoon Y; Chae MK; Lee EJ; Yoon JS
Graefes Arch Clin Exp Ophthalmol; 2020 May; 258(5):1095-1102. PubMed ID: 31900640
[TBL] [Abstract][Full Text] [Related]
39. Human placenta-derived mesenchymal stem cells ameliorate orbital adipogenesis in female mice models of Graves' ophthalmopathy.
Park M; Banga JP; Kim GJ; Kim M; Lew H
Stem Cell Res Ther; 2019 Aug; 10(1):246. PubMed ID: 31399042
[TBL] [Abstract][Full Text] [Related]
40. Phospholipase C-γ as a Potential Therapeutic Target for Graves' Orbitopathy.
Roh TH; Chae MK; Ko JS; Kikkawa DO; Jang SY; Yoon JS
Endocrinol Metab (Seoul); 2023 Dec; 38(6):739-749. PubMed ID: 37989267
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
